Combination treatment modalities in cutaneous T-cell lymphoma (CTCL)

Joan Guitart*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

A wide variety of cutaneous T-cell lymphoma therapies are now used in clinical practice. Treatment options include phototherapy, radiation, topical therapy, systemic mono-chemotherapy, combination chemotherapy, and combined modalities. Many patients fail or develop resistance to monotherapy, resulting in a need for combined treatment modalities to improve therapeutic results in terms of quality of life and duration of response. Recently, bexarotene, a selective antagonist of the retinoid X receptor, has been approved in the treatment of patients with cutaneous T-cell lymphoma. Bexarotene offers new opportunities for combination treatment strategies because of its novel and unique mechanism of action. In this article we review the rationale and examine key published evidence on combining these new treatment modalities.

Original languageEnglish (US)
Pages (from-to)17-20
Number of pages4
JournalSeminars in Oncology
Volume33
Issue numberSUPPL. 3
DOIs
StatePublished - Feb 2006

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Combination treatment modalities in cutaneous T-cell lymphoma (CTCL)'. Together they form a unique fingerprint.

Cite this